Skip to search formSkip to main contentSkip to account menu

edoxaban

Known as: Ethanediamide, n1-(5-chloro-2-pyridinyl)-n2-((1s,2r,4s)-4- ((dimethylamino)carbonyl)- 2-(((4,5,6,7-tetrahydro-5-methylthiazolo(5,4-c)pyridin-2-yl)carbonyl)amino)cyclohexyl)-, N-(5-chloropyridin-2-yl)-N'-[(1S,2R,4S)-4-(N,N-dimethylcarbamoyl)-2-(5-methyl-4,5,6,7- tetrahydro[1,3]thiazolo[5,4-c]pyridine-2-carboxamido)cyclohexyl]oxamide, N-(5-chloropyridin-2-yl)-N'-((1S,2R,4S)-4-(N,N-dimethylcarbamoyl)-2-(5-methyl-4,5,6,7- tetrahydro(1,3)thiazolo(5,4-c)pyridine-2-carboxamido)cyclohexyl)oxamide 
An orally active inhibitor of coagulation factor Xa (activated factor X) with anticoagulant activity. Edoxaban is administered as edoxaban tosylate… 
National Institutes of Health

Related topics

Related topics

11 relations

Narrower (4)

DU-176DU-176bSavaysaedoxaban tosylate

Broader (3)

Factor Xa inhibitorsPyridinesThiazoles
Letaxabanedoxaban 30 MG Oral Tabletedoxaban 60 MGedoxaban 60 MG Oral Tablet [Savaysa]

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2019
2019
Clinical Benefit of Direct Oral Anticoagulants Versus Vitamin K Antagonists in Patients with Atrial Fibrillation and Bioprosthetic Heart Valves.
Review
2019
Review
2019
Anticoagulant selection for patients with VTE—Evidence from a systematic literature review of network meta‐analyses
2016
2016
Embolic Stroke, Atrial Fibrillation, and Microbleeds: Is There a Role for Anticoagulation?
A 73-year-old man presents with an ischemic stroke. Work-up reveals paroxysmal atrial fibrillation (AF), and magnetic resonance… 
2016
2016
Clinical impact and course of major bleeding with edoxaban versus vitamin K antagonists
Summary Edoxaban is a once-daily direct oral anticoagulant (DOAC). The Hokusai-VTE study revealed that, after initial treatment… 
2015
2015
Hemorrhagic complications of dental extractions in 181 patients undergoing double antiplatelet therapy.
Review
2014
Review
2014
Treatment of patients with acute deep vein thrombosis and/or pulmonary embolism: efficacy and safety of non-VKA oral anticoagulants in selected populations.
2014
2014
Abstract 16612: Efficacy and Safety of Edoxaban for the Management of Elderly Patients With Atrial Fibrillation: Engage AF-TIMI 48
Background: Elderly patients with atrial fibrillation (AF) treated with anticoagulants are at higher risk of both ischemic and… 
2013
2013
Evaluation of edoxaban in patients with atrial fibrillation and severe renal impairment
Purpose: Compare safety and pharmacokinetics of edoxaban (EDX) 15 mg, an oral selective FXa inhibitor, in patients with… 
2012
2012
Edoxaban administration following enoxaparin: A pharmacodynamic, pharmacokinetic, and tolerability assessment in human subjects
Summary Edoxaban is an oral direct factor (F)Xa inhibitor in advanced stages of clinical development. The primary objective of… 
Review
2010
Review
2010
New options with dabigatran etexilate in anticoagulant therapy
Thrombosis, the localized clotting of blood, occurs in both the arterial and venous circulation, and has a major impact on health… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)